Man Group plc acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 245,492 shares of the company's stock, valued at approximately $9,149,000. Man Group plc owned approximately 0.28% of IDEAYA Biosciences at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of IDYA. Royal Bank of Canada raised its stake in IDEAYA Biosciences by 30.1% in the first quarter. Royal Bank of Canada now owns 122,460 shares of the company's stock worth $2,006,000 after buying an additional 28,322 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of IDEAYA Biosciences by 8.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,044 shares of the company's stock worth $938,000 after acquiring an additional 4,308 shares during the period. Millennium Management LLC grew its holdings in shares of IDEAYA Biosciences by 345.2% during the 1st quarter. Millennium Management LLC now owns 547,637 shares of the company's stock worth $8,970,000 after acquiring an additional 424,625 shares during the period. American Century Companies Inc. grew its holdings in shares of IDEAYA Biosciences by 862.7% during the 2nd quarter. American Century Companies Inc. now owns 114,644 shares of the company's stock worth $2,410,000 after acquiring an additional 102,736 shares during the period. Finally, Norges Bank bought a new position in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $643,000. 98.29% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on IDYA shares. Wedbush lifted their price target on IDEAYA Biosciences from $58.00 to $60.00 and gave the company an "outperform" rating in a research report on Wednesday, August 5th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a report on Friday, May 22nd. Mizuho lowered their price objective on IDEAYA Biosciences from $52.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, May 7th. Royal Bank Of Canada reduced their target price on shares of IDEAYA Biosciences from $53.00 to $48.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 7th. Finally, Wall Street Zen lowered shares of IDEAYA Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Fourteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of "Moderate Buy" and an average price target of $50.12.
Check Out Our Latest Stock Analysis on IDEAYA Biosciences
IDEAYA Biosciences Price Performance
Shares of IDEAYA Biosciences stock opened at $40.11 on Friday. The stock has a market cap of $3.52 billion, a price-to-earnings ratio of -20.68 and a beta of -0.10. The firm's 50-day moving average is $37.17 and its 200 day moving average is $33.17. IDEAYA Biosciences, Inc. has a 1 year low of $23.23 and a 1 year high of $42.68.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.06) by ($0.16). The firm had revenue of $8.86 million for the quarter, compared to the consensus estimate of $8.02 million. IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. The firm's revenue for the quarter was up 8800.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.88) earnings per share. On average, equities analysts expect that IDEAYA Biosciences, Inc. will post -4.38 EPS for the current fiscal year.
Insider Buying and Selling at IDEAYA Biosciences
In related news, CAO Briseno Andres Ruiz sold 9,550 shares of the business's stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total value of $382,095.50. Following the completion of the transaction, the chief accounting officer directly owned 26,466 shares in the company, valued at $1,058,904.66. The trade was a 26.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.70% of the stock is owned by company insiders.
IDEAYA Biosciences Profile
(
Free Report)
IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA's pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.
Central to IDEAYA's approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.
Featured Articles
Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider IDEAYA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list.
While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
